Organ Care System (OCS) Lung System
TransMedics, Inc. · Decision date May 13, 2026
What did the FDA approve?
FDA records P160013/S021 as a supplement to PMA P160013, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 13, 2026.
FDA approval order statement
approval for material, supplier, and design changes to the filter cap and raw material and supplier changes to the pleated filter assembly
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- May 13, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P160013/S021
- Regulatory pathway
- PMA supplement
- Applicant
- TransMedics, Inc.
- Product code
- QBA
- Decision code
- APPR
- Decision date
- May 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic machine perfusion system for the preservation of standard criteria donor lungs prior to transplantation.
- Applicant
- TransMedics, Inc.
- Product code
- QBA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160013 · Original PMA
Organ Care System (OCS) Lung System
P160013/S019 · Related supplement
Organ Care System (OCS) Lung System
P160013/S021 received
Application receipt date recorded by FDA.
P160013/S020 · Related supplement
Organ Care System (OCS) Lung System
P160013/S021 · FDA decision
Real-Time Process
P160013/S023 · Related supplement
Organ Care System (OCS) Lung System
Timeline entries are records held by MedtechLedger for P160013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| TransMedics, Inc. | PMA approval | Mar 22, 2018 | FDA | |
Organ Care System (OCS) Lung SystemP160013/S019 | TransMedics, Inc. | PMA supplement | Oct 22, 2025 | FDA |
Organ Care System (OCS) Lung SystemP160013/S020 | TransMedics, Inc. | PMA supplement | Dec 16, 2025 | FDA |
Organ Care System (OCS) Lung SystemP160013/S023 | TransMedics, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
TransMedics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 200 Minuteman Rd., Suite 302, Andover, MA, 01810
Sources and methodology
- Original FDA record: P160013/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


